Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
ROCKVILLE, Md., Feb. 27, 2017 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the company and host investor meetings at the Cowen & Company 37th Annual Health Care Conference.
Date: Wednesday, March 8, 2017
Time: 10:40 a.m. ET
Place: The Boston Marriott Copley Place, Boston, Mass.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 Or Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
